发明名称 |
ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV GP350/220 |
摘要 |
<p>The present invention provides vaccine adjuvants comprising the Epstein Barr Virus glycoprotein 350/220 or naturally occuring variants thereof, a fusion protein comprising EBV Gp350/220 sequence which binds to the CR2 receptor, o r a synthetically-derived fragment of Gp350/220 which retains the ability to bind to the CR2 receptor. The present invention further provides immunostimulatory compositions comprising an EBV Gp350/220 adjuvant sequence that binds the CR2 complex and at least one antigen of interest other than Gp350/220. Co-administration of the adjuvant with an antigen of interest, other than an antigen comprising EBV 350/220 sequence, enhances the immunogenicity of the antigen. In a preferred embodiment, the adjuvant is directly or indirectly covalently bound to an antigen of interest to form an immunogenic composition. In a most preferred embodiment of the composition, antibodies are elicited against at least one Gp350/220 epitope and against a t least one epitope of the antigen.</p> |
申请公布号 |
CA2331258(A1) |
申请公布日期 |
1999.12.16 |
申请号 |
CA19992331258 |
申请日期 |
1999.06.10 |
申请人 |
HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE |
发明人 |
MOND, JAMES J.;LEES, ANDREW |
分类号 |
C12N15/09;A61K39/245;A61K39/385;A61K39/39;C07K14/05;C07K19/00;C12N15/38;C12R1/93;(IPC1-7):C12N15/38;C12N15/63 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|